On Tuesday, Canaccord Genuity made an adjustment to its price target for Zimmer Biomet (NYSE:ZBH), a medical device company, reducing it to $120 from the previous target of $130, while keeping a Hold rating on the stock. The firm's decision comes as a response to a reassessment of the company's valuation compared to its peers.
The revised price target is based on a forward-looking earnings multiple. Canaccord Genuity applies a 13.8 times price-to-earnings (P/E) ratio for the year 2024 to Zimmer Biomet's projected earnings per share (EPS) for 2025, which is estimated at $8.65. This P/E multiple represents a 56% discount to the average of the firm's broad large-cap MedTech group, excluding the highest and lowest values.
The adjustment in the price target reflects a more conservative valuation compared to the prior assessment. Canaccord Genuity's analyst noted the rationale behind the decrease, stating a greater discount was applied to Zimmer Biomet's peer group in comparison to their previous valuation.
Zimmer Biomet specializes in manufacturing medical devices, particularly in the musculoskeletal healthcare sector. The company provides solutions that support orthopedic surgeons and clinicians in improving patient outcomes.
The current Hold rating indicates that Canaccord Genuity does not see significant upside or downside potential from the stock's last closing price, suggesting that investors maintain their positions without increasing or decreasing their exposure significantly. The new price target of $120 provides a reference point for investors regarding the firm's expectations of the stock's future price performance.
Zimmer Biomet Holdings (NYSE:ZBH), Inc. has made significant strides in its financial and strategic operations. The company recently completed a $700 million financial transaction involving the issuance of notes due in 2034, providing additional capital for the firm. In a move to expand its technological capabilities, Zimmer Biomet is set to acquire OrthoGrid Systems, a company specializing in AI-driven surgical guidance. The acquisition includes OrthoGrid's flagship Hip AI system and over 40 patents.
Stifel analysts have adjusted Zimmer Biomet's shares target to $130 from $135, maintaining a Buy rating despite the company's mixed performance in the second quarter of 2024.
Zimmer Biomet has also secured $2.5 billion in credit facilities as part of its strategy to maintain a robust liquidity position.
The company's moves towards AI integration, strategic acquisitions, and financial fortification demonstrate its focus on future expansion and resilience.
InvestingPro Insights
As Zimmer Biomet (NYSE:ZBH) navigates through the evolving landscape of the medical device industry, real-time data from InvestingPro provides further context to Canaccord Genuity's revised price target. Zimmer Biomet's management has shown confidence in the company's value through aggressive share buybacks, a move that often indicates a belief in undervalued stock. Additionally, the company has demonstrated a commitment to shareholder returns, maintaining dividend payments for 13 consecutive years, which may appeal to income-focused investors.
InvestingPro data highlights Zimmer Biomet's current market cap of $22.76 billion and a P/E ratio of 23.16, with an adjusted P/E ratio over the last twelve months as of Q2 2024 at a lower 18.2. This adjusted P/E ratio aligns with the company's near-term earnings growth, trading at a low P/E ratio relative to this growth (PEG Ratio: 0.23). Despite the recent downward revisions in earnings by 22 analysts for the upcoming period, Zimmer Biomet's stock generally trades with low price volatility, which might be preferred by investors seeking stability in their portfolio. The company's profitability over the last twelve months and the analysts' prediction that it will remain profitable this year provide a reassuring signal for potential investors.
For those looking to delve deeper into Zimmer Biomet's financials and future prospects, InvestingPro offers additional insights and metrics. There are currently more tips available on the platform, which can be accessed at: https://www.investing.com/pro/ZBH.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.